Table 2.
Dose of first, and last, intake by gender, baseline body weight, and baseline ECOG PS
| Dose of first intake | Dose of last intakea | |||||||
|---|---|---|---|---|---|---|---|---|
| Patients (N) | 20 mg, n (%) |
30 mg, n (%) |
40 mg, n (%) |
20 mg, n (%) |
30 mg, n (%) |
40 mg, n (%) |
50 mg, n (%) |
|
| All | 1602 | 115 (7.2) | 246 (15.4) | 1241 (77.5) | 454 (28.3) | 554 (34.6) | 580 (36.2) | 13 (0.8) |
| Gender | ||||||||
| Male | 655 | 28 (4.3) | 85 (13.0) | 542 (82.7) | 129 (19.7) | 222 (33.9) | 298 (45.5) | 6 (0.9) |
| Female | 947 | 87 (9.2) | 161 (17.0) | 699 (73.8) | 325 (34.3) | 332 (35.1) | 282 (29.8) | 7 (0.7) |
| Body weight (kg) | ||||||||
| <50 | 606 | 68 (11.2) | 123 (20.3) | 415 (68.5) | 198 (32.7) | 214 (35.3) | 189 (31.2) | 4 (0.7) |
| 50 to < 60 | 513 | 33 (6.4) | 76 (14.8) | 404 (78.8) | 160 (31.2) | 184 (35.9) | 167 (32.6) | 2 (0.4) |
| 60 to < 70 | 307 | 10 (3.3) | 38 (12.4) | 259 (84.4) | 64 (20.8) | 110 (35.8) | 130 (42.3) | 3 (1.0) |
| ≥70 | 169 | 4 (2.4) | 9 (5.3) | 156 (92.3) | 30 (17.8) | 44 (26.0) | 91 (53.8) | 4 (2.4) |
| ECOG PS | ||||||||
| 0 | 642 | 33 (5.1) | 78 (12.1) | 531 (82.7) | 191 (29.8) | 218 (34.0) | 226 (35.2) | 7 (1.1) |
| 1 | 739 | 54 (7.3) | 110 (14.9) | 575 (77.8) | 208 (28.1) | 257 (34.8) | 267 (36.1) | 6 (0.8) |
| 2 | 143 | 18 (12.6) | 39 (27.3) | 86 (60.1) | 36 (25.2) | 50 (35.0) | 57 (39.9) | 0 |
| 3 | 63 | 8 (12.7) | 17 (27.0) | 38 (60.3) | 14 (22.2) | 25 (39.7) | 24 (38.1) | 0 |
| 4 | 15 | 2 (13.3) | 2 (13.3) | 11 (73.3) | 5 (33.3) | 4 (26.7) | 6 (40.0) | 0 |
ECOG PS, Eastern Cooperative Oncology Group performance status
aOne patient, a female with body weight < 50 kg and ECOG PS of 1, received a last dose of afatinib of 10 mg